It has recently been shown that hepatocyte growth factor activator inhibitor-2 (HAI-2) is able to suppress carcinogenesis induced by overexpression of matriptase, as well as cause regression of individual established tumors in a mouse model system. However, the role of HAI-2 is poorly understood. In this study, we describe 3 mutations in the binding loop of the HAI-2 Kunitz domain 1 (K42N, C47F and R48L) that cause a delay in the SEA domain cleavage of matriptase, leading to accumulation of non-SEA domain cleaved matriptase in the endoplasmic reticulum (ER). We suggest that, like other known SEA domains, the matriptase SEA domain auto-cleaves and reflects that correct oligomerization, maturation, and/or folding has been obtained. Our results suggest that the HAI-2 Kunitz domain 1 mutants influence the flux of matriptase to the plasma membrane by affecting the oligomerization, maturation and/or folding of matriptase, and as a result the SEA domain cleavage of matriptase. Two of the HAI-2 Kunitz domain 1 mutants investigated (C47F, R48L and C47F/R48L) also displayed a reduced ability to proteolytically silence matriptase. Hence, HAI-2 separately stabilizes matriptase, regulates the secretory transport, possibly via maturation/oligomerization and inhibits the proteolytic activity of matriptase in the ER, and possible throughout the secretory pathway.
-2. 8 Genetic inactivation of either HAI-1 or HAI-2 in mice leads to failure of placental labyrinth formation. 9, 10 However, this defect can be completely rescued by simultaneously reducing or eliminating matriptase expression. 10, 11 A wealth of evidence has coalesced within the last decade to indicate that matriptase is highly oncogenic unless kept under strict post-translational regulation by HAI-1 and/or HAI-2. 12, 13 In addition, deregulated matriptase has been shown to single-handedly cause squamous cell carcinoma formation in transgenic mice overexpressing wild-type matriptase in the epidermis. 14, 15 A simultaneous increase in either HAI-1 or HAI-2 expression completely negates the oncogenic potential caused by matriptase overexpression. 14, 15 Furthermore, upregulation of HAI-2 expression has been shown to cause regression of already established individual tumors in mice. 14 However, the way by which HAI-1 and HAI-2 exerts this post-translational control of matriptase is still poorly understood.
Matriptase is a modular,~95 kDa, protease that consists of a short cytoplasmic N-terminal peptide, a signal anchor that functions as a single-pass transmembrane domain, a sea urchin sperm protein, enteropeptidase, and agrin (SEA) domain (residues 86-201), 2 complement C1r/s urchin embryonic growth factor and bone morphogenetic protein-1 (CUB) domains (residues 214-334), 4 low-density lipoprotein receptor class A (LDLRa) domains (residues 452-604) and a trypsin-like serine protease domain (SPD) (residues 614-855) [16] [17] [18] [19] ( Figure 1A ).
Matriptase is synthesized as a single chain pro-form. The newly synthesized matriptase, expressed in the absence of HAI-2 and HAI-1, can only be detected at very low levels in cells, whereas matriptase coexpressed together with HAI-1 or HAI-2 can be detected in high amounts on the plasma membrane of cells in culture, 20 and for HAI-2 also in genetically engineered mice, 21 thus suggesting that the membrane bound form of matriptase expressed without HAI-1 and HAI-2 becomes destabilized by an unknown mechanism. 20 It has previously been shown that matriptase mutated in either G827R (causing congenital ichthyosis) or S805A (active site mutated matriptase) is able to escape this unknown mechanism 22 and consequently, matriptase G827R and matriptase S805A can be readily detected independently of HAI-1 and HAI-2 using SDS-PAGE and western blotting.
Newly synthesized matriptase is, by hydrolysis of the Gly149-Ser150 peptide bond located within the SEA domain, converted into the SEA domain cleaved form of matriptase. The cleaved matriptase remains attached to the membrane by non-covalent interactions within the SEA domain. 23 The SEA domain cleavage takes place in the secretory pathway, as only the SEA domain cleaved form of the matriptase mouse orthologue, epithin, has been found on the surface of cells. 24 It FIGURE 1 Mutation of amino acids 149 and 150, flanking the SEA domain cleavage site, generates a high molecular weight non-SEA domain cleaved form of matriptase. A, Schematic representation of the structures of matriptase, hepatocyte growth factor activator inhibitors-1 and -2 (HAI-1) and (HAI-2). Including the approximate binding sites for the matriptase antibodies used, M24 and IM1014 (blue). B, HEK293 cells transiently transfected with matriptase alone or together with HAI-1 or HAI-2, as well as matriptase G149E, matriptase G149N, matriptase S150G, matriptase S805A and matriptase G827R alone or together with HAI-1 or HAI-2. Extracts obtained by lysis were analyzed using SDS-PAGE and western blotting (WB), using antibodies against matriptase (IM1014 under boiled and reducing conditions, and M24 under boiled conditions), HAI-1 and HAI-2. Non-SEA domain cleaved and SEA domain cleaved matriptase can be distinguished using the antibody IM1014, on samples that are boiled and reduced, or using the antibody M24, on samples that are boiled but not reduced. The positions of non-SEA domain cleaved matriptase, SEA domain cleaved matriptase, HAI-1 and HAI-2 are indicated with illustrations to the right. Molecular mass markers (kDa) are indicated to the left. The results are representative of at least 3 independent experiments. Several blots have been used to make up this figure, however, all combinations have been compared on single blots.
is generally believed that the SEA domain cleaved matriptase subsequently becomes proteolytically cleaved after Arg614 in the SPD domain (zymogen conversion), 25, 26 generating the Arg614 cleaved form (also denoted as the activated form or the two chain form) ( Figure 1A ).
The Arg614 cleaved matriptase rapidly makes a complex with HAI-1, whereby it becomes proteolytically silent. [27] [28] [29] HAI-1 and HAI-2 are closely related transmembrane serine protease inhibitors, each consisting of two extracellular Kunitz-type protease inhibitor domains, followed by a C-terminal transmembrane domain 30, 31 ( Figure 1A ). In addition, HAI-1 also contains an extracellular low-density lipoprotein receptor (LDLR) domain and a motif at N-terminus with eight-cysteines (MANEC) domain, recently shown to have a PAN/apple domain-type fold. 30, 32 HAI-2 primarily resides within the endoplasmic reticulum (ER). 20 In contrast to HAI-2, HAI-1 is exocytosed to the basolateral plasma membrane and subsequently transcytosed to the apical plasma membrane. 29 A missense mutation in HAI-2, Y163C, is known to cause an autosomal recessive form of congenital sodium diarrhea 33 by an unknown mechanism.
In this study, we analyzed the functions of HAI-2 towards matriptase using transient expression in Humane embryonic kidney 293
(HEK293) cells. None or very low levels of HAI-1, HAI-2 and matriptase are endogenously expressed in these cells, as tested by immunohistochemistry, SDS-PAGE and western blotting (data not shown). In accordance, none/low levels of recombinant expressed matriptase could be detected, unless when stabilized by co-expression with either HAI-1 or HAI-2 ( Figure 1B) . In order to focus on the interactions of newly synthesized matriptase taking place in the early secretory pathway, matriptase mutated in position Gly149 or Ser150, flanking the SEA domain cleavage site, were studied. It has previously been shown, that HAI-2 favors binding to this early non-SEA domain cleaved form of matriptase, as compared with the SEA domain cleaved form. 21 In this paper we describe three individual mutations of the HAI-2 Kunitz domain 1 that results in delayed SEA domain cleavage and accumulation of matriptase in the ER, and of these three, two also displayed a reduced ability to proteolytically silence matriptase.
| RESULTS

| Mutation of amino acids Gly149 and Ser150
, flanking the matriptase SEA domain cleavage site, generates a high molecular weight non-SEA domain cleaved form of matriptase
In this study, we aim to investigate the interactions between matriptase and HAI-2 in the secretory pathway. Thus, our focus is mainly on the non-SEA domain cleaved form of matriptase. SEA domain cleavage of matriptase occurs between amino acid residues Gly149 and Ser150
( Figure 1A ). To prevent SEA domain cleavage, the amino acids on either side of the cleavage site were mutated, generating matriptase cDNAs encoding matriptase G149E, matriptase G149N and matriptase S150G.
To confirm that these three mutated forms of matriptase are unable to SEA domain cleave, HEK293 cells were transiently transfected with expression plasmids for matriptase, matriptase G149E, matriptase G149N and matriptase S150G, alone, or co-expressed together with either HAI-1 or HAI-2. The extracts obtained by lysis were analyzed using SDS-PAGE and western blotting ( Figure 1B were determined using the peptide-based chromogenic substrate, isoleucil-prolyl-arginine-p-nitroaniline (S-2288) ( Figure 4A ). This substrate is known to be readily cleaved by a broad spectrum of serine proteases, including the SPD of matriptase. 20 Extracts from mock- controls ( Figure 4A ). These results also showed a significant increase in chromogenic activity in the cell extracts co-expressing matriptase G149E with HAI-2 C47F or HAI-2 R48L, as compared with the activity level of cell extracts co-expressing matriptase G149E with HAI-2 wild-type, thus suggesting that HAI-2 is able to proteolytically silence both matriptase wild-type and matriptase G149E and that this ability can be compromised by the HAI-2 Kunitz domain 1 mutations C47F
and R48L, but not K42N.
Another experiment was carried out to confirm that the chromo- with HAI-2 C47F, as compared with wild-type matriptase together with HAI-2 C47F, thus suggesting that the increase in activity Each column represents the mean value for the rate of turnover from at least 3 independent transfections with the corresponding standard deviation indicated. The setups were repeated at least 3 times and displayed consistent value patterns. The rate of substrate turnover was determined from color development detected at 405 nm and all measurements were adjusted for the optical path length and a background sample, prepared with lysis buffer and indicated as mAU/min. All data have been manually reviewed and adjusted for irregularities. Significant differences in the turnover rate are indicated with the corresponding P-values (no star; P > .05, *P ≤ .05, ** P ≤ .01, *** P ≤ .001) by Student's t test. D, Extracts from (B) were subjected to SDS-PAGE and western blotting (WB) using antibodies against matriptase (IM1014, boiled and reduced) or 
| Matriptase co-expressed with HAI-2 Kunitz domain 1 mutants K42N, C47F or R48L is retained in the ER
We have previously shown that HAI-2 mainly colocalizes with an ER marker, 20 
| The SEA domain cleavage and shedding of matriptase co-expressed with HAI-2 Kunitz domain 1 mutants K42N, C47F or R48L is reduced
Non-SEA domain cleaved matriptase is normally not present on the plasma membrane, 28 correlating with the majority of the matriptase, exhibiting delayed SEA domain cleavage when co-expressed with HAI-2 mutants K42N, C47F or R48L, being located predominantly in the ER. To examine, whether any matriptase, when co-expressed with FIGURE 5 Matriptase co-expressed with hepatocyte growth factor activator inhibitor-2 (HAI-2) Kunitz domain 1 mutants K42N, C47F or R48L colocalize with an endoplasmic reticulum marker, unlike wild-type HAI-2. HEK293 cells were transiently transfected, co-expressing matriptase with either wild-type, or mutated HAI-2, as indicated to the left, and the vector pDsRed2-ER, expressing an ER marker, and grown on cover slips for 2 days. The cells were fixed and stained with antibodies against matriptase (green) and the cell surface-marker phalloidin (targeting F-actin) (blue). The cells were visualized using confocal microscopy. Treatment with Biotin-RQRR-CMK, that is known to bind and inhibit active matriptase in the plasma membrane, 37 did not clearly FIGURE 7 Matriptase co-expressed with compromised hepatocyte growth factor activator inhibitor-2 (HAI-2) mutants leads to increased intracellular unopposed matriptase activity. HEK293 cells were transiently transfected in triplicates with matriptase together with wild-type HAI-2, HAI-2 Kunitz domain 1 mutants (C47F, R48L, C47F/R48L), and wild-type HAI-1 (as indicated on the x-axis). Cells were subjected to surface treatment with NHS-SS-Biotin (middle columns) labeling plasma membrane proteins in a non-specific manner, Biotin-RQRR-CMK (right columns) specifically labeling active serine proteases and inhibiting the serine protease activity of matriptase, and with PBS++ (untreated, left columns). Cells were then extracted by lysis (total extract fraction, black columns), followed by pull down of Biotin with streptavidin coated-resin (pull down fraction, dark grey columns), and the supernatant, after pull down, was saved (supernatant fraction, light grey columns). Each column represents the rate of turnover of the chromogenic substrate S-2288, determined continuously at 405 nm (A 405 ) every 5 minutes for 5 hours during incubation at 37 C for the total extract and the supernatant fractions. The pull down fractions were incubated at end-over-end at 37 C and a total of 5 samples were taken during a 4 hours incubation and end point A 405 was measured. The rate of substrate turnover was determined from color development and all measurements were adjusted for the optical path length and a background sample prepared with lysis buffer and indicated as mAU/min. The level of GAPDH in the total extract fractions was determined after boiling using SDS-PAGE and western blotting, to ensure a consistent cell quantity for all transfections, the blots are placed below each corresponding transfection. The results are representative of 3 independent experiments.
reduce the level of chromogenic activity in the supernatants (Figure 7 , supernatant) as compared with cells treated with NHS-SSBiotin. The non-cell permeant agent Biotin-RQRR-CMK is thus, unable to react with the majority of the unopposed matriptase activity in cells co-expressing matriptase and a compromised HAI-2, supporting that the chromogenic activity has an intracellular location.
| DISCUSSION
We have previously shown that co-expression with HAI-1 or HAI-2 is necessary for the stability of matriptase in vitro. 20 None of the HAI-2 mutants analyzed in this study affected the ability of HAI-2 to stabilize matriptase (Figure 2 ). 39 one of which is disrupted by the mutation C47F, stabilize the compact structure of the HAI-2 Kunitz domain 1. It has previously been shown that the two other disulphide bonds, but not the one disrupted by C47F, are required for the maintenance of native conformation of a Kunitz domain. 42 The HAI-2 R48-A49 bond is positioned in a way that mimics an expected cleavage site (P1-P1 0 ) targeted by the catalytic S residue and other catalytic triad residues of the protease. Concerning peptide substrates, matriptase prefers an R in the P1 position, as found in both the Kunitz domain 1 (R48) and Kunitz domain 2 (R143) of HAI-2, and its S2 position is shaped to fit a small hydrophobic amino acid residue. 43, 44 Thus, the HAI-2 mutation C47F at the predicted P2 position, and R48L at the predicted P1 position, would be expected to disfavor insertion of the HAI-2 binding loop into the active site cleft of matriptase, and as a result have reduced ability to proteolytically silence matriptase.
Matriptase resembles most other enzymes, where zymogen conversion results in an activated form with a higher catalytic activity.
However, the difference in activity between the zymogen form (not cleaved after Arg614) and the activated form (Arg614 cleaved) is unusually small for matriptase, only in the order of 27 fold (the zymogenicity factor). 37, 45, 46 There are no known specific substrates or inhibitors of matriptase available. Therefore, the general level of proteolysis was assessed using a chromogenic substrate, recognized by most serine proteases. The increase in chromogenic activity observed in the cell extracts co-expressing matriptase with the HAI-2
Kunitz domain 1 mutants C47F or R48L ( Figure 4A ) appears to stem directly from, or at least require, the presence of activated matriptase (Arg614 cleaved), as no/lower increase in activity was observed using the matriptase mutant R614A (the activation cleavage site mutation) together with HAI-2 C47F ( Figure 4B ). It is possible that the observed activity does not stem directly from matriptase, but rather from other proteases activated by matriptase. However, it is safe to conclude that the observed increase in chromogenic activity in the extracts reflects, either directly or indirectly, the catalytic activity of matriptase.
In this setup, detection of the matriptase Arg614 cleaved SPD fragment could not be used to indicate activation of matriptase, as no clearly defined matriptase SPD band was observed (~30 kDa) ( Figures 2, 4 and 6 ). This may be because only a minor fraction of the matriptase molecules were activated, under the conditions used in this study.
We observed three HAI-2 Kunitz domain 1 mutants, K42N, C47F
and R48L that lead to reduced levels of SEA domain cleavage when Overall, these findings suggest that the reduced levels of SEA domain cleaved matriptase, observed with the HAI-2 Kunitz domain 1 mutants, are a result of delayed matriptase SEA domain cleavage rather than the result of increased matriptase activation and/or shedding.
The increased unopposed matriptase activity, observed when matriptase is co-expressed with a compromised HAI-2 (C47F, R48L
or C47F/R48L), was primarily observed with an intracellular localization ( Figure 7 ) and was somewhat unaffected by extracellular inhibition with Biotin-RQRR-CMK ( Figure 7) . Furthermore, matriptase coexpressed with these compromised HAI-2s was found to colocalize with an ER marker ( Figure 5 ) and to be mainly in the non-SEA domain cleaved form (Figure 2 ). Based on these findings, we suggest that a and HAI-1, 47 and for matriptase and pancreatic trypsin inhibitor. 43 An unusually large binding interface was observed between the SPD of matriptase and HAI-1, in the order of 1800 Å, 2,47 which corresponds well with the strong binding observed between matriptase and HAI-1, as the complex can withstand separation on an SDS-PAGE gel. 48 Similarly, the matriptase-HAI-2 complex has been reported to withstand separation on an SDS-PAGE gel 49 , thus supporting the presence of at least one unknown ectosite where matriptase and HAI-2 interacts. It is possible, that a HAI-2-matriptase interaction at an undiscovered ectosite is responsible for the stabilization of the membrane-bound form of matriptase; however, it is at present time unclear where this ectosite is located.
Generally, each domain in a multi-domain protein like matriptase is a stable globular structure of polypeptide chain(s) representing an autonomous folding unit. 50 SEA domains are found in a range of proteins, the structure is well known 51 and they often have the ability to auto-cleave. 52 If the SEA domain of matriptase is able to auto-cleave, we expect it to take place independently of for example HAI-1 and HAI-2. Accordingly, this study and others 25 have observed that matriptase S805A, matriptase G827R 22, 25 and matriptase R614A (this study) SEA domain cleave independently of HAI-1 and HAI-2 ( Figures 1 and 4D ). We suggest that the matriptase SEA domain auto-cleaves, and that it reflects when the correct 3-dimensional fold of the domain has been obtained.
It is well known that, for some proteins, transport out of the ER is retained until proper oligomerization and folding have taken place. 50, 53 In this study, we observed that co-expression of matriptase with HAI-2 Kunitz domain 1 mutants K42N, C47F or R48L delayed the SEA domain cleavage of matriptase, and caused matriptase to be retained predominantly in the ER (Figures 1 and 5 ). When labeling matriptase at the plasma membrane, mainly SEA domain cleaved matriptase was observed, and only SEA domain cleaved matriptase was detected in the media, when matriptase was co-expressed with the three HAI-2
Kunitz domain 1 mutants ( Figure 6A,B) , suggesting that only SEA domain cleaved matriptase is competent for transport to the plasma membrane and subsequent shedding. Thus, HAI-2 may influence matriptase folding and/or oligomerization and thereby control the flux of matriptase to the plasma membrane, where matriptase can cleave several extracellular substrates. 54, 55 However, it seems that the retention of non-SEA domain cleaved matriptase can be exhausted, as matriptase mutated in the SEA domain cleavage site (matriptase G149N, matriptase G149E and matriptase S150G) co-expressed together with wild-type HAI-2, was detected on the plasma membrane in the non-SEA domain cleaved form.
HAI-2 K42N and C47F were designed based on SNP's (rs35896127 and rs1804770) that occur at very low frequencies. No phenotype has been associated with these SNP's. However, it would be highly interesting to know whether carriers of C47F (rs1804770) have an affected cancer incidence, because unopposed matriptase has been reported to be highly oncogenic. 14, 15 In conclusion, our results suggest that HAI-2 plays an important role in the stabilization of matriptase, regulation of matriptase activity and in obtaining the correct fold/oligomeric state necessary to allow transport of matriptase from the ER to the plasma membrane.
Most proteases are synthesized in the zymogen form and then transported to wherever they perform their action, and becomes acti- been located on the plasma membrane. 49 We suggest that the pur- 
| MATERIALS AND METHODS
| Cell culture
The human embryonic kidney cell line HEK293 was grown in minimal essential medium supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin at 37 C in an atmosphere of 5% CO 2 . For experiments, cells were seeded 1 day prior into either 6-or 12-well Corning Costar cell culture plates (cat. no. CLS3512 or CLS3516, Sigma) and grown to 80% confluence.
| Transfections and DNA constructs
For transient expression, adherent HEK293 cells were transfected using Lipofectamine 2000 (Invitrogen), according to the protocol supplied by the manufacturer. For co-transfections the same overall quantity of plasmid was used. The cDNA coding for full-length human wild-type matriptase, HAI-1 and HAI-2 were incorporated into pcDNA3.1 plasmid vectors. The HAI-2 cDNA used in this study contains a naturally occurring SNP resulting in the amino acid substitution V200L. Construction of the HA-HAI-2 plasmid has previously been described. 21 Empty expression plasmids were used for mock 
| SDS-PAGE and western blotting
Samples were prepared by addition of 2 × SDS sample buffer (1:1) and for reducing conditions 0.2 M dithiothreitol (DTT) was added.
Proteins were separated on either 7% or 10% SDS polyacrylamide gels and transferred to Immobilon-P PVDF membranes (Millipore).
The blots were blocked with 10% non-fat dry milk in PBS containing 
| Antibodies
Blots were probed with primary monoclonal mouse anti-human matriptase antibodies, M24 56 (1:2000) recognizing both non-SEA Thermo Scientific), prepared as described by the manufacturer.
After incubation, the streptavidin-coated resin was pulled down (2000g, 30 seconds), for the chromogenic activity assay a sample of the supernatant was saved for instant analysis (supernatant fraction). The pull down for western blotting was washed 4 times with 25 mM Tris-HCl, 500 mM NaCl, 0.5% Triton-X-100 pH 7.8 and 3 times with 10 mM Tris-HCl, 150 mM NaCl pH 7.8. Proteins for western blotting were eluted from the streptavidin-coated resin by boiling in 2× SDS sample buffer and analyzed using SDS-PAGE and western blotting. The pull down for chromogenic activity analysis was washed 1 time with 25 mM Tris-HCl, 500 mM NaCl, 0.5% Triton-X-100 pH 7.8 and instantly used for the chromogenic activity assay (pull down fraction). 
| Immunofluorescence
| Chromogenic activity assay
Extracts obtained by lysis of transiently transfected HEK293 cells, For detection of chromogenic substrate activity on streptavidincoated resin, HBS buffer containing 300 μM chromogenic substrate S-2288 was added to the pull down and samples were incubated at 37 C with end-over-end rotation for 4 hours. Samples were spun (2000g, 1 minutes) and 150 μL was removed 5 times during the incubation and A 405 was measured and the mean velocity of the substrate reactions (mAU/min) was calculated for each reaction. The rate of substrate turnover was determined from color development resulting from the pseudo-first order reaction due to a substrate concentration far greater than the expected pM range of protease content, as judged by semi-quantitative western blot analysis. All measurements were adjusted for the optical path length and a background sample prepared with lysis buffer and indicated as mAU/min.
